Answers are grounded in this paper and cite their sources.
BACKGROUND: Agomelatine is a melatonergic receptor agonist and a 5HT2C receptor antagonist that has shown antidepressant efficacy. In order to analyze separately the effect of the two receptorial components, rats were chronically treated with agomelatine, melatonin (endogenous melatonergic agonist), or S32006 (5-HT2C antagonist), and then subjected to acute footshock-stress. RESULTS: Only chronic agomelatine, but not melatonin or S32006, completely prevented the stress-induced increase of glutamate release in the rat prefrontal/frontal cortex. CONCLUSIONS: These results suggest a potential synergy between melatonergic and serotonergic pathways in the action of agomelatine.
No takes yet. Share an insight, caveat, or question.
Tardito et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: